Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension safety study of subcutaneous methylnaltrexone in advanced illness with opioid-induced constipation
2007-006107-20Phase 4Terminated
- Sponsor
- Salix Pharmaceuticals
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methylnaltrexone in opioid-induced constipation (OIC), sponsored by Salix Pharmaceuticals. Primary endpoint: Safety evaluation. Started Mar 2008; status: terminated.
02
Drugs
methylnaltrexone
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on 2007-006107-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006107-20.